Shares of BioNTech BNTX rose 7% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 586.67% year over year to ($1.03), which missed the estimate of ($0.42).
Revenue of $78,831,000 higher by 151.99% year over year, which beat the estimate of $63,840,000.
Outlook
BioNTech hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Nov 10, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/jqhpczzu
Technicals
Company's 52-week high was at $115.00
Company's 52-week low was at $17.07
Price action over last quarter: Up 63.65%
Company Profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, and does not yet have any commercialized medicines.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
